Table III.
ADCs and CAR-Ts targeting transmembrane or GPI-anchored proteins other than DLL3, NOTCH3 and RTKs.
| Target | Type | Drug name | Alias | Stage of drug development | (Refs.) |
|---|---|---|---|---|---|
| BCMA | ADC | GSK2857916 | Phase II (registration no. NCT03525678; multiple myeloma; active NR) | (238) | |
| BCMA | CAR-Ts | Bb2121 | Phase III (registration no. NCT03651128; multiple myeloma; recruiting) | (193) | |
| CD19 | CAR-Ts | Axicabtagene ciloleucel | KTE-C19 | FDA approval (B-cell NHL) | (181) |
| CD19 | CAR-Ts | Tisagenlecleucel | CTL019 | FDA approval (B-cell ALL & NHL) | (182) |
| CD22 | ADC | Inotuzumab ozogamicin | CMC-544 | FDA approval (B-cell ALL) | (183) |
| CD30 | ADC | Brentuximab vedotin | SGN-35 | FDA approval (ALCL, HL, mycosis fungoides & PTCL) | (184) |
| CD33 | ADC | Gemtuzumab ozogamicin | CMA-676 | FDA approval (AML) and subsequent withdrawal | (239) |
| CD56 | ADC | Lorvotuzumab mertansine | IMGN901 | Phase II (registration no. NCT02452554; pediatric tumors; active NR) | (240) |
| CD79B | ADC | Polatuzumab vedotin | DCDS4501A | FDA approval (diffuse large B-cell lymphoma) | (185) |
| CD142 | ADC | Tisotumab vedotin | TF-ADC | Phase I/II (registration no. NCT02001623; solid tumors; completed in 2018) | (241) |
| CD205 | ADC | MEN1309 | OBT076 | Phase I (registration no. NCT03403725; solid tumors; recruiting) | (194) |
| CEACAM5 | ADC | Labetuzumab govitecan | IMMU-130 | Phase I/II (registration no. NCT01605318; colorectal cancer; completed in 2017) | (242) |
| CLDN18 | ADC | Anti-CLDN18.2 ADC | Preclinical study (rodent) | (243) | |
| CLDN18 | CAR-Ts | CAR-CLDN18.2 | Phase I (registration no. NCT03159819; Gas & Panc; recruiting) | (195) | |
| FOLR1 | ADC | Mirvetuximab soravtansine | IMGN853 | Phase III (registration no. NCT02631876; ovary; active NR) | (190) |
| GFRA1 | ADC | hu-6D3.v5-vcMMAE | Preclinical study (rodent & primate) | (244) | |
| GPNMB | ADC | Glembatumumab vedotin | CDX-011 | Phase II (registration no. NCT02302339; melanoma; terminated in 2018) | (245) |
| LGR5 | ADC | Anti-LGR5-mc-vc-PAB-MMAE | Preclinical study (rodent) | (246) | |
| LRRC15 | ADC | Samrotamab vedotin | ABBV-085 | Phase I (registration no. NCT02565758; solid tumors; completed in 2019) | (247) |
| LYPD3 | ADC | Lupartumab amadotin | BAY 1129980 | Phase I (registration no. NCT02134197; solid tumors; completed in 2018) | (248) |
| MSLN | ADC | Anetumab ravtansine | BAY 94-9343 | Phase II (registration no. NCT03023722; Panc; active NR) | (249) |
| NECTIN4 | ADC | Enfortumab vedotin | ASG-22ME | Phase III (registration no. NCT03474107; urothelial cancer; recruiting) | (191) |
| SLC34A2 | ADC | Lifastuzumab vedotin | DNIB0600A | Phase II (registration no. NCT01991210; ovarian cancer; completed in 2016) | (250) |
| SLC39A6 | ADC | Ladiratuzumab vedotin | SGN-LIV1A | Phase I/II (registration no. NCT03310957; TNBC; recruiting) | (251) |
| TROP2 | ADC | Sacituzumab govitecan | IMMU-132 | Phase III (registration no. NCT02574455; TNBC; recruiting) | (192) |
Active NR, active, not recruiting; ADC, antibody-drug conjugate; ALCL, anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Breast, breast cancer; CAR-Ts, chimeric antigen receptor-modified T cells; CD142, Tissue factor; Gas, gastric cancer; HL, Hodgkin lymphoma; MSLN, Mesothelin; NHL, non-Hodgkin lymphoma; Ovary, ovarian, fallopian tube or primary peritoneal cancer; Panc, pancreatic cancer; PTCL, peripheral T-cell lymphoma; RTK, receptor tyrosine kinase, SCLC, small-cell lung cancer; TNBC, triple-negative breast cancer; FDA, Food and Drug Administration; BCMA, tumor necrosis factor receptor superfamily member 17; CEACAM5, carcinoembryonic antigen-related cell adhesion molecule 5; CLDN18, Claudin 18.2; FOLR1, folate receptor-α; GFRA1, GDNF family receptor α1; GPNMB, transmembrane glycoprotein NMB; LGR5, leucine-rich repeat-containing G-protein coupled receptor 5; LRRC15, leucine-rich repeat-containing protein 15; LYPD3, Ly6/PLAUR domain-containing protein 3; MSLN, mesothelin; SLC34A2, sodium-dependent phosphate transport protein 2B; SLC39A6, zinc transporter SIP6; TROP2, tumor-associated calcium signal transducer 2.